Summary
This project aims to define the population-based incidence of influenza-associated serious neuropsychiatric symptoms in children and to test the hypothesis that oseltamivir use is associated with these adverse events, including modification by P-gp modulating drugs.
What they want
The project will leverage data from the Tennessee Medicaid (TennCare) program, which includes vital statistics, pharmacy claims, and hospital administrative data for over 750,000 children annually. The studies will define the incidence of influenza-associated serious neuropsychiatric symptoms, test the association between oseltamivir and serious neuropsychiatric adverse events (NPAEs), and investigate how concurrent use of P-gp modulating drugs modifies this risk. The candidate will also pursue advanced coursework in pharmacoepidemiology, leadership training, and practical experiences with the FDA and Children's Hospital Association to develop expertise in pharmacoepidemiology and drug safety.
Deliverables
- Define the population-based incidence of influenza associated serious neuropsychiatric symptoms in children
- Test the hypothesis that oseltamivir is associated with serious NPAE
- Test the hypothesis that concurrent use of drugs modulating P-gp modifies the risk of oseltamivir associated serious NPAE
Technical requirements
- Leverage data from the Tennessee Medicaid (TennCare) program comprising vital statistics, pharmacy claims data, and hospital administrative data
Key personnel
- Clinical investigator
- Multidisciplinary team of mentors and advisors (experts in pediatrics, pharmacoepidemiology, clinical pharmacology, infectious disease, epidemiology)
